Yang Qing, He Liyun, Quan Xin, Liang Yan
National Clinical Research Center of Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 100037 Beijing, China.
Emergency Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 100037 Beijing, China.
Rev Cardiovasc Med. 2022 Jun 27;23(7):243. doi: 10.31083/j.rcm2307243. eCollection 2022 Jul.
Patients with ventricular thrombus (VT) require anticoagulation therapy and it remains unknown that whether non-vitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) are more effective.
We aimed to compare the effectiveness and safety of NOACs with VKAs on the rate of thrombus resolution and clinical outcomes.
MEDLINE, PUBMED, EMBASE, Cochrane Library, Web of Science, China National Knowledge Infrastructure Database and Wanfang Database, were searched up to November 22, 2021. The primary outcome was the rate of thrombus resolution, and the secondary outcomes were bleeding, stroke or systemic embolism (SSE), stroke and all-cause death. Odds ratio (OR) and 95% confidential intervals (CI) were used for the pooled results.
Eighteen studies with 1755 participants (NOACs, n = 607; VKAs, n = 1148) were included. There were no significant differences in thrombus resolution (OR 0.92, 95% CI 0.68-1.23, = 0.558), bleeding (OR 0.85, 95% CI 0.54-1.35, = 0.496), SSE (OR 0.77, 95% CI 0.41-1.43, = 0.401), stroke (OR 0.65, 95% CI 0.29-1.49, = 0.312) or all-cause death (OR 1.02, 95% CI 0.63-1.67, = 0.925) between NOACs and VKAs. Subgroup analyses showed a statistics difference in thrombus resolution between NOACs and VKAs among studies which enrolled patients with or without dabigatran (Yes: OR 0.80, 95% CI 0.59-1.08; No: OR 1.48, 95% CI 1.00-2.19; = 0.01), while no significances were observed according to baseline characteristics.
Our findings showed that NOACs were comparable to VKAs in thrombus resolution as well as clinical outcomes. In studies that enrolled patients without dabigatran, the thrombus resolution seemed to be greater in NOACs group than VKAs group. And in different proportion of baseline left ventricular ejection fraction, history of ischemic cardiomyopathy and combination with antiplatelet, the thrombus resolution among the two groups remained similar.
心室血栓(VT)患者需要抗凝治疗,目前尚不清楚非维生素K拮抗剂口服抗凝剂(NOACs)或维生素K拮抗剂(VKAs)哪种更有效。
我们旨在比较NOACs与VKAs在血栓溶解率和临床结局方面的有效性和安全性。
检索MEDLINE、PUBMED、EMBASE、Cochrane图书馆、科学网、中国知网数据库和万方数据库,检索截至2021年11月22日的文献。主要结局是血栓溶解率,次要结局是出血、卒中或全身性栓塞(SSE)、卒中和全因死亡。汇总结果采用比值比(OR)和95%置信区间(CI)。
纳入18项研究,共1755名参与者(NOACs组607例;VKAs组1148例)。在血栓溶解(OR 0.92,95%CI 0.68-1.23,P = 0.558)、出血(OR 0.85,95%CI 0.54-1.35,P = 0.496)、SSE(OR 0.77,95%CI 0.41-1.43,P = 0.401)、卒中(OR 0.65,95%CI 0.29-1.49,P = 0.312)或全因死亡(OR 1.02,95%CI 0.63-1.67,P = 0.925)方面,NOACs与VKAs之间无显著差异。亚组分析显示,在纳入或未纳入达比加群的患者的研究中,NOACs与VKAs在血栓溶解方面存在统计学差异(是:OR 0.80,95%CI 0.59-1.08;否:OR 1.48,95%CI 1.00-2.19;P = 0.01),而根据基线特征未观察到显著差异。
我们的研究结果表明,NOACs在血栓溶解以及临床结局方面与VKAs相当。在未纳入达比加群患者的研究中,NOACs组的血栓溶解似乎比VKAs组更显著。并且在不同比例的基线左心室射血分数、缺血性心肌病病史以及联合使用抗血小板药物的情况下,两组之间的血栓溶解情况仍然相似。